Generative AI is rapidly entering oncology, from literature review and medical writing to trial prescreening and clinical ...

Long-term exposure to cigarette smoke reshapes distinct populations of lung stem cells, and the reshaped cell state deciding ...

Engineered bacteria are moving from curiosity to a funded platform. A five-year, $13.1 million National Institutes of Health ...

Children, Families, and the 2026 Revised Blood Guidance for Jehovah's Witnesses - An Update for Pediatric Hematology and ...

CAR-T therapy, which transformed the treatment of B-cell blood cancers, is now being tested as a way to reset the immune system in severe ...

Neil Kramer, MD, is a rheumatologist at Atlantic Health Overlook Medical Center, Physician Researcher, Atlantic Health ...

Breast Cancer Awareness Month has evolved far beyond a public-health campaign. Over four decades, patient advocacy, philanthropy, data collection, molecular science, and increasingly sophisticated ...

In a market where biotech venture funding has rebounded sharply but investors are more selective, Chris Ehrlich, CEO of CERo Therapeutics, argues that capital strategy matters as much as scientific ...

Calvin Chao, MD, MBA, Vice President of Medical Science at Artera, is a medical executive with expertise spanning oncology, molecular diagnostics, artificial intelligence, and medical affairs. At ...

Artificial intelligence (AI) is increasingly used in oncology to support tasks such as clinical-trial matching, evidence review, mammography, digital pathology, cancer biology, and drug discovery.

Diagnosis and patient communication account for about 60% of the trial set. These are the two largest categories by a wide margin, and they sit at opposite ends of the care pathway. Diagnostic ...

Breast cancer prevention remains an important opportunity to move care earlier in the disease continuum, particularly by addressing measurable risk factors such as mammographic breast density (MBD).